Figure 2. Schematic capturing our... | American Society of Hematology

Figure 2.

$Schematic capturing our current general approach for relapsed or refractory patients with AML with some factors guiding the clinical decision process. Risk stratification by 2017 ELN criteria.14 Approved targeted inhibitors include gilteritinib (FLT3), ivosidenib (IDH1), enasidenib (IDH2). *Assuming patient has already received intensive consolidation. **Randomized phase 3 data are only currently available for gilteritinib,6 not ivosidenib or enasidenib. †HMA alone if venetoclax unavailable. FLAG-IDA, fludarabine/cytarabine/granulocyte colony-stimulating factor/idarubicin; HiDAC, high-dose cytarabine; HMA, hypomethylating agent; IDH, isocitrate dehydrogenase; LoDAC, low-dose cytarabine; MEC, mitoxantrone/etoposide/cytarabine; PIF, primary induction failure.$

Schematic capturing our current general approach for relapsed or refractory patients with AML with some factors guiding the clinical decision process. Risk stratification by 2017 ELN criteria.¹⁴ Approved targeted inhibitors include gilteritinib (FLT3), ivosidenib (IDH1), enasidenib (IDH2). *Assuming patient has already received intensive consolidation. **Randomized phase 3 data are only currently available for gilteritinib,⁶ not ivosidenib or enasidenib. †HMA alone if venetoclax unavailable. FLAG-IDA, fludarabine/cytarabine/granulocyte colony-stimulating factor/idarubicin; HiDAC, high-dose cytarabine; HMA, hypomethylating agent; IDH, isocitrate dehydrogenase; LoDAC, low-dose cytarabine; MEC, mitoxantrone/etoposide/cytarabine; PIF, primary induction failure.

This Feature Is Available To Subscribers Only